I'll take a crack at that one.
We assess the pharmaceutical comparatively. We're looking at product A versus product B. And it's not just on their clinical effectiveness. It also looks at the cost effectiveness. We take into consideration the adverse effects profile, how much more effective one is over the other. We would never recommend a physician or a drug plan to cover a drug that is not effective. It does need to have some effectiveness and it has to demonstrate a greater therapeutic benefit over the existing drugs.